Compare peptides

Compare peptides

Choose any two compounds below to see them side by side. Each comparison page lines up the level of evidence behind each one, the registered clinical trials, and where each stands with regulators, so the differences are easy to see in one place.

This is a side-by-side of what is documented, not a ranking. Different compounds are studied for different things, in different people, at different amounts. A row that looks stronger for one compound does not make it the better choice for anyone.

ATX-304Survodutide
Highest evidence tier on the pageE2 Human clinical evidence
Registered or peer-reviewed human trial with reported results.
E2 Human clinical evidence
Registered or peer-reviewed human trial with reported results.
Regulatory statusIn clinical development, not approvedIn clinical development, not approved
Research areaMetabolic and incretinMetabolic and incretin
Regulator-approved dose on fileNo approved doseNo approved dose
Molecular formulaC16H11Cl2N3O2SC192H289N47O61, from a chemical supplier data sheet only, not confirmed against a peer-reviewed or regulatory source
Molar mass380.2 g/mol (free form, PubChem)4231.7, from a chemical supplier data sheet only, not confirmed against a peer-reviewed or regulatory source
CAS number1261289-04-6 (free form); 2639972-26-0 (sodium salt)2805997-46-8, from vendor catalogues, and salt-form assignments in those catalogues are not reliable
Registered trials on this site2 in the tracker14 in the tracker
Furthest registered phasePhase 3Phase 3
Trials currently active02
Trial sponsorsBristol-Myers Squibb, Boehringer IngelheimBoehringer Ingelheim
Published trials covered on its page37
Amounts studied in those trialsTELLUS Phase IIa (Steneberg et al., JCI Insight 2018): 1,000 mg per day as a suspension; doses per day and route not stated for 28 days
Phase 1b (ADA abstract 1782-P and Cambrian Bio release, June 2026): 400 mg by mouth once daily or placebo for 8 weeks, then optional open-label extension to 16 weeks
Multiple-ascending-dose Phase 1 (ObesityWeek 2026 Poster-111, Cambrian Bio, November 14, 2026): 400 mg once daily or 400 mg twice daily, or placebo; route not stated on the panels reviewed for 4 weeks
As reported on the compound page. Amounts are not comparable between compounds.
NCT04153929: Survodutide up to 0.3, 0.9, 1.8 or 2.7 mg once weekly, or 1.2 or 1.8 mg twice weekly, against placebo and open label semaglutide up to 1.0 mg once weekly for 16 weeks
NCT04667377: Survodutide 0.6, 2.4, 3.6 or 4.8 mg once weekly, or placebo, 1:1:1:1:1 for 46 weeks, 20 weeks of escalation then 26 weeks of maintenance
NCT04771273: Survodutide 2.4, 4.8 or 6.0 mg once weekly, or placebo, 1:1:1:1 for 48 weeks, 24 weeks of rapid escalation then 24 weeks of maintenance
As reported on the compound page. Amounts are not comparable between compounds.
What is not knownThe number of doses per day, the route and the human pharmacokinetics in the 2018 TELLUS trial. The paper gives the daily total of 1,000 mg and the word suspension only. The formulation and starting values of the 2026 Phase 1b (the November 2026 poster...Whether survodutide raises energy expenditure in a human being. That is the central mechanistic claim made for the compound, it rests on rodent indirect calorimetry that reached significance at one dose on two days with no change in core temperature or activity, and it has...

Full pages: ATX-304 and Survodutide. See also the clinical trial tracker and how we grade evidence.

Educational reference, not medical advice. Trial data from ClinicalTrials.gov. Everything else is drawn from the compound pages on this site, each of which cites its sources.

Most requested comparisons

These are the pairings readers look for most often. Each opens a full side-by-side page.

Weight management compounds

Growth hormone related peptides

Repair and recovery

Longevity, mitochondria and brain

How to read a comparison

A side-by-side table can make two compounds look equally proven when they are not. Keep these points in mind as you read.

  • Evidence level matters more than the headline. Every compound is placed on the same six-tier scale, from published human clinical trials down to community reports. A compound with large human trials and one with only animal studies are not comparable, even when both appear in the same table.
  • Registered trials show what is being tested. A trial listed on ClinicalTrials.gov tells you a question is being studied, not that the answer is known. Check the status and phase. You can browse every tracked study on the clinical trial tracker and see recent registry updates in the trial changes feed.
  • Regulatory status is specific to a formulation and a country. Approval of one product does not mean every version of that compound is approved.
  • Different populations and doses limit direct comparison. Results from separate trials, run in different people over different periods, cannot be lined up as if they came from a head-to-head study unless a comparison page says a head-to-head study exists.

Frequently asked questions

Which compound is better?

These pages do not rank compounds or tell anyone what to use. They show what the published and registered evidence says about each one so you can see where the evidence is strong and where it is thin.

Why are some comparisons mostly empty on one side?

Many popular peptides have little or no human trial data. When that is the case, the comparison says so plainly rather than filling the gap with community claims.

Can I compare doses here?

Reported amounts are documented on each individual peptide page, with the source and evidence tier for every figure. If you need to work out concentrations, the reconstitution calculator is a math tool only and does not suggest an amount.

Where can I see every compound?

The full peptide library lists every entry,.

PeptideBlog is an educational reference compiled from public sources. It is not medical advice, and nothing here is a recommendation for or against any compound.

Share thisFacebookXEmail